Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.85 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.85 |
| ▸ | MLNR | O43193 | 1/20 | 0.85 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | GAA | P10253 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | DRD2 | P14416 | 1/20 | 0.85 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.85 |
| ▸ | HTR2C | P28335 | 1/20 | 0.85 |
| ▸ | MC4R | P32245 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL3335 | 0.95 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3896385 | 0.95 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL308488 | 0.95 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2120068 | 0.95 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL5935753 | 0.94 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3649623 | 0.93 | SLC6A2 (0.80) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL309402 | 0.93 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2109339 | 0.93 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL991500 | 0.92 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.92 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008093360-A2 | A PROCESS FOR PREPARATION OF (S)-(+)-N-METHYL-3(1-NAPHTHYLOXY)-3(2-THIENYL)PROPYLAMINE HYDROCHLORIDE | USV LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008081476-A2 | PROCESS FOR PREPARING DULOXETINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-07-10 | — | — | WO | disclosed |
| EP-1730132-A2 | PROCESS FOR PREPARING PHARMACEUTICALLY ACCEPTABLE SALTS OF DULOXETINE AND INTERMEDIATES THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2006-12-13 | — | — | EP | disclosed |
| US-20060194869-A1 | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-08-31 | — | — | US | disclosed |
| WO-2006071868-A2 | PROCESS FOR PREPARING PHARMACEUTICALLY ACCEPTABLE SALTS OF DULOXETINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194869-A1 | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof | UGT1A4, UGT2B7, UGT1A8 | SLC6A2 27/4885SLC6A4 8/4885SLC6A3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.